Kamla B.Molecular Medicine Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
About Kamla B.Molecular Medicine
Kamla B.Molecular Medicine Private Limited (KBMPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 May 2020 (Four years and nine months 24 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Disha Kalra and Nisha Nisha serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33100DL2020PTC363507
- Company No.
363507
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 2020
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Kamla B.Molecular Medicine Private Limited offer?
Kamla B.Molecular Medicine Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit.
Who are the key members and board of directors at Kamla B.Molecular Medicine?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Disha Kalra  | Director | 01-May-2020 | Current |
| Nisha Nisha | Director | 01-May-2020 | Current |
Financial Performance of Kamla B.Molecular Medicine.
Enhance accessibility to Kamla B.Molecular Medicine's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kamla B.Molecular Medicine?
Unlock access to Kamla B.Molecular Medicine's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kamla B.Molecular Medicine?
Kamla B.Molecular Medicine has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kamla B.Molecular Medicine, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kamla B.Molecular Medicine's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.